🇺🇸 FDA
Patent

US 11007186

Methods of treating RBP4 related diseases with triazolopyridines

granted A61KA61K31/4545A61K31/4985

Quick answer

US patent 11007186 (Methods of treating RBP4 related diseases with triazolopyridines) held by Belite Bio, Inc expires Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Belite Bio, Inc
Grant date
Tue May 18 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 13 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/4545, A61K31/4985, A61K31/519, A61K31/5365